2026-10-02 FDA Warning Letter: Hanlim Pharm Co., Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
In short: On October 2, 2026, FDA's Center for Drug Evaluation and Research issued a warning letter to Hanlim Pharm Co., Ltd. (FEI 3004886113, Seoul, South Korea) following an inspection April 16-24, 2026, documenting CGMP violations in the manufacture of sterile finished pharmaceuticals. The FDA identified failures in aseptic procedures and cleanroom design, including operators breaching first air over open sterile materials, inadequate smoke studies showing unidirectional airflow deficiencies that exposed critical processing areas to lower-classified air, and poor personnel practices; the company's May 15, 2026 response proposing line redesign and training was deemed inadequate due to insufficient monitoring programs and quality assurance oversight.
Argus analysis
# FDA Warning Letter Analysis: Hanlim Pharm Co., Ltd.
## Company and Violations
Hanlim Pharm Co., Ltd., a South Korean pharmaceutical manufacturer, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on October 2, 2026, following an inspection of its facility in Gyeonggi-do conducted April 16–24, 2026. The FDA documented significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished sterile pharmaceuticals. The agency determined that Hanlim's manufacturing methods, facilities, and controls do not conform to CGMP standards, rendering its drug products adulterated under federal law.
## Regulatory Citations and Their Meaning
The warning letter cites 21 CFR parts 210 and 211, which establish baseline CGMP requirements for drug manufacturing. Specific violations include 21 CFR 211.113(b), governing aseptic processing validation; 21 CFR 211.42(c), requiring segregation to prevent contamination or mix-ups; and 21 CFR 211.110(a), mandating control procedures for manufacturing processes. These citations address fundamental sterility assurance mechanisms. The FDA documented operators breaching aseptic barriers, inadequate airflow patterns in cleanrooms, insufficient sterilization of equipment surfaces (relying instead on wiping with disinfectants), deficient environmental monitoring programs, and inadequate visual inspection with significant defect rates. These findings collectively suggest systemic failures in contamination prevention.
## Response Timeline and Industry Monitoring
Hanlim submitted a response to the FDA Form 483 on May 15, 2026, which the agency deemed inadequate. The company proposed redesigning filling lines and decommissioning certain production equipment but lacked sufficient oversight mechanisms and independent airflow assessments. Compliance officers should monitor whether Hanlim submits a comprehensive corrective action plan addressing airflow visualization, personnel monitoring, equipment sterilization, and environmental controls. Industry peers should note this case as a cautionary example; similar facilities should expect heightened FDA scrutiny of aseptic operations, smoke studies, and cleanroom design if comparable deficiencies exist.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Hanlim Pharm Co., Ltd. MARCS-CMS 734782 — October 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Reference #: 320-27-03 Product: Drugs Recipient: Recipient Name Mr. Jungjin Kim Recipient Title Chairman Hanlim Pharm Co., Ltd. Seocho-Daero, 52-Gil 42 Seongdong-gu Seoul South Korea (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 2, 2026 WARNING LETTER Reference number: 320-27-03 To Mr. Jungjin Kim: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA Inspection Violations were observed and documented during an inspection of your drug manufacturing facility, Hanlim Pharm Co., Ltd., FDA Establishment Identifier (FEI) 3004886113, at 2-27 Yeongmun-ro, Yonginsi Ceoin-gu, Gyeonggi-do, from April 16 to April 24, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your May 15, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)). Poor Aseptic Practices and Cleanroom Behavior You manufacture sterile, (b)(4) drug products (including (b)(4) ). We observed poor aseptic practices during set-up an…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Hanlim Pharm Co., Ltd. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Hanlim Pharm Co., Ltd. as of 2026-10-13. Argus ingests new FDA enforcement records daily.
- What FDA violations was Hanlim Pharm Co., Ltd. cited for?
- The FDA Warning Letter to Hanlim Pharm Co., Ltd. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Hanlim Pharm Co., Ltd.?
- FDA issued the letter (MARCS-CMS 734782) on 2026-10-02 and posted it publicly on fda.gov on 2026-10-13.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-10-02 FDA Warning Letter: Hanlim Pharm Co., Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-hanlim-pharm-co-ltd-2026-10-02-cgmp
"2026-10-02 FDA Warning Letter: Hanlim Pharm Co., Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-hanlim-pharm-co-ltd-2026-10-02-cgmp.
Argus HQ Research. "2026-10-02 FDA Warning Letter: Hanlim Pharm Co., Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed October 14, 2026. https://argushq.ai/fda/warning-letter/fda-wl-hanlim-pharm-co-ltd-2026-10-02-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_hanlim_pharm_co_ltd_2026_10_02_cgmp_2026,
title = {2026-10-02 FDA Warning Letter: Hanlim Pharm Co., Ltd. Cited for CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-hanlim-pharm-co-ltd-2026-10-02-cgmp},
note = {Accessed: October 14, 2026}
}